Key result
VAD bridging in pediatric retransplant achieves ~71% survival, but mortality is higher with BTC versus BTT.
Why the study?
The use of ventricular assist devices to bridge pediatric heart transplant recipients to retransplantation is rare and under-studied.
Does ventricular assist device support effectively bridge pediatric heart transplant recipients to heart retransplantation with favorable survival outcomes?
Observational (n=24)
Yes
Does ventricular assist device support effectively bridge pediatric heart transplant recipients to heart retransplantation with favorable survival outcomes?
In the first multicenter study of pediatric patients supported with a VAD as a bridge to heart retransplantation, 71% survived to retransplant and 88% survived at 1 year post-retransplant despite high rates of on-device adverse events.
Answers are grounded in this paper and cite their sources.
VAD bridging to pediatric retransplant shows feasibility despite frequent adverse events; extends single-center data but leaves optimal selection open for prospective study.
The use of ventricular assist devices (VAD) in pediatric patients as a bridge to heart transplantation has increased over the past two decades. However, the use of VAD to bridge pediatric transplant recipients to retransplantation is rare and under-studied. We performed a retrospective study using the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry to evaluate patient characteristics and clinical outcomes in patients bridged to retransplant with VAD. A total of 24 patients were identified and supported for a median duration of 64 days (interquartile range [IQR]: 15.0-101.25). Of these, 54% (n = 13) were implanted as a bridge to retransplant candidacy (BTC) and 46% (n = 11) as a bridge to retransplant (BTT). We found a high prevalence of major adverse events, including infection in 75% (n = 18), bleeding in 42% (n = 10), renal dysfunction requiring dialysis in 33% (n = 8), and stroke in 8% (n = 2). Despite this, 71% (n = 17) survived to retransplant, with an 88% 1 year survival following retransplant. Device mortality was higher in BTC compared to BTT (46% vs. 9%; p = 0.046). Our study is the first multicenter study evaluating the use of VAD as a BTT. We exhibit a high prevalence of adverse events on VAD, but a favorable waitlist and post-retransplant survival.
No takes yet. Share an insight, caveat, or question.
Lukich et al. (2026) conducted an observational in Pediatric heart transplant recipients requiring retransplantation (n=24). Ventricular assist device (VAD) support as bridge to retransplant candidacy (BTC) or bridge to retransplant (BTT) vs. Bridge to retransplant candidacy (BTC, n=13) vs bridge to retransplant (BTT, n=11) was evaluated on Survival to heart retransplantation (with device mortality compared between BTC and BTT) (p=0.046). Ventricular assist device bridging in pediatric heart transplant recipients yielded 71% survival to retransplant, with higher mortality in BTC vs BTT.
Synapse has enriched 10 related papers. Consider them for comparative context: